CFR Chemaphor Inc.

Thanks to strong turnout at two veterinarian training meetings held recently in
Southwestern Ontario, over 100 small animal and horse veterinarians in Canada
are now trained and accredited to perform VetStem RC Regenerative Cell Therapy
on patients. 


VetStem RC Regenerative Cell Therapy is a cutting-edge treatment that captures
the natural healing power of an animal's own adipose (fat) tissue. In Canada,
procedure training and cell processing is offered to veterinarians through
Avivagen Animal Health Inc., a Canadian company dedicated to developing
science-based, natural health products for companion animals and offering
veterinarians alternatives to traditional treatments.


"Regenerative cell therapy procedures have been used to improve mobility and
quality of life in over 8000 companion animals to date," Dr. Corey Orava,
keynote speaker at the mid-February training sessions, told veterinarians in
attendance. "This is no longer an experimental treatment, but an important tool
in the veterinarian's arsenal to improve quality of life in companion animals
and return performance animals to full potential," he added. Dr. Orava is
Veterinary Services Manager with Vet-Stem, Inc., the company that developed the
treatment in the U.S. 


VetStem RC Regenerative Cell Therapy is scientifically proven for treatment of
arthritic conditions and joint and ligament injuries in dogs, cats and horses.
The therapy uses regenerative cells derived from an animal's own adipose tissue.
A small amount of fat tissue is extracted by the patient's veterinarian, and
then couriered to Avivagen Animal Health's new, state-of-the-art, Canadian
laboratory facility. The cells are processed and counted, following stringent
sterility and quality assurance guidelines. The number of doses required for the
immediate treatment are then returned to the veterinarian for injection into the
patient, often within 48 hours of extraction. Extra doses are stored by Avivagen
Animal Health for future treatments. 


"The seminar was an excellent introduction to the topic of stem cell therapy.
Through VetStem RC Regenerative Cell Therapy, Avivagen Animal Health is proving
to be on the forefront of stem cell technology," commented Dr. Ian Sandler, a
small animal veterinarian with Rosedale Animal Hospital in Toronto, Ontario.
"Clearly there are benefits of stem cell therapy for small animals with chronic
issues such as arthritis and joint inflammation. There is a certain need for
this type of technology and the safety profile appears to be a great option for
older dogs and cats. There is definite place for the use of this therapy in our
practices and we are looking to initiate this treatment option in many
patients."


"Stem cell therapies may now offer new treatments for horses suffering from
career ending tendon and ligament damage, as well as potential treatment for
osteoarthritis (joint disease)," said Dr. Laura Frost, an equine veterinarian
with Halton Equine Veterinary Services in Puslinch, Ontario. "Although there is
still a lot that we do not fully understand, there is a strong future for this
therapy and I believe we are just at the tip of the iceberg. This is a treatment
that can offer true healing rather than merely masking signs of disease."


Avivagen Animal Health is a new Canadian company dedicated to improving the
quality of life of animals through science-based, natural health products proven
in clinical trials and sold exclusively through veterinarians. Avivagen Animal
Health is a subsidiary of Chemaphor Inc., a Canadian company dedicated to the
research and development of science-based, natural products for people and
animals. VetStem RC Regenerative Cell Therapy has been exclusively licensed by
Avivagen Animal Health for the Canadian animal health market from Vet-Stem
(USA).


Chemaphor, a federally incorporated, publicly listed, biotechnology company (TSX
Venture Exchange; symbol CFR.v), has core biological and chemistry expertise,
focused on the development of nutriscience products. 


VetStem RC Regenerative Cell Therapy is licensed from Vet-Stem, Inc.

Forward Looking Statements

This news release includes certain forward-looking statements that are based
upon current expectations, which involve risks and uncertainties associated with
the business of Chemaphor Inc. and Avivagen Animal Health Inc. and the
environment in which their respective businesses operate. Any statements
contained herein that are not statements of historical facts may be deemed to be
forward-looking, including those identified by the expressions "will",
"anticipate", "believe", "plan", "estimate", "expect", "intend", and similar
expressions. The forward-looking statements reflect the current expectations of
Chemaphor Inc. and Avivagen Animal Health Inc. regarding future results or
events. These forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results or events to differ materially
from current expectations. Chemaphor assumes no obligation to update the
forward-looking statements, or to update the reasons why actual results could
differ from those reflected in the forward-looking statements. The results of
treatment described above are based on historical results. Different animals may
experience different results from the treatments described above. Anyone
interested in the treatments described above should discuss the potential
benefits and risks of such treatments with their veterinarian.

Chemaphor Inc. (TSXV:CFR)
Historical Stock Chart
From Jun 2024 to Jul 2024

Chemaphor Inc. (TSXV:CFR)
Historical Stock Chart
From Jul 2023 to Jul 2024